In the following video, Motley Fool health care bureau chief Brenton Flynn continues his look at Intuitive Surgical's (NASDAQ:ISRG) annual report. Specifically, he takes a look at one possible new competitive threat emerging on the company's radar. The company, called IMRIS, has its primary focus on intraoperative MRI technology, but is currently conducting clinical trials for a surgical platform targeting neurological conditions. Brenton tells investors whether this company is a concern and what other competitive threats Intuitive might be facing.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Intuitive Surgical. The Motley Fool owns shares of Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Better Buy: Intuitive Surgical, Inc. vs. Accuray, Inc.
Which stock wins in a head-to-head battle between these innovative medical-device companies?
3 Growth Stocks With Virtual Monopolies
These three companies have built ironclad fortresses around their business operations.
Why Intuitive Surgical, Inc. Shareholders Have Something to Worry About
Runaway success for this pioneer of robot-assisted surgery has inspired a slew of competitors to enter the arena.